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Abstract
Prokineticin receptor 1 (PKR1) and its ligand Bv8 were shown to be expressed in inflammation-
induced pain and by tumor-supporting fibroblasts. Blocking this receptor might prove useful for
reducing pain and for cancer therapy. However, there is no method to quantify the levels of these
receptors in vivo.
Methods—A nonpeptidic PKR1 antagonist, N-{2-[5-(4-fluoro-benzyl)-1-(4-methoxy-
benzyl)-4,6-dioxo-1,4,5,6-tetrahydro-[1,3,5] triazin-2-ylamino]-ethyl}-guanidine, which contains
a free guanidine group, was labeled with 18F by reacting the guanidine function with N-
succinimidyl-4-18F-fluorobenzoate to give the guanidinyl amide N-(4-18F-fluoro-benzoyl)-N′-{2-
[5-(4-fluoro-benzyl)-1-(4-methoxy-benzyl)-4,6-dioxo-1,4,5,6-tetrahydro-[1,3,5] triazin-2-
ylamino]-ethyl}-guanidine (18F-PC-10). Inflammation was induced in C57BL/6 mice by
subcutaneous injection of complete Freund adjuvant in the paw. The mice were imaged with 18F-
PC-10, 18F-FDG, and 64Cu-pyruvaldehyde bis(4-methyl-3-thiosemicarbazone) (64Cu-PTSM) at 24
h after complete Freund adjuvant injection using a small-animal PET device.
Results—18F-PC-10 was synthesized with a radiochemical yield of 16% ± 3% (decay-
corrected). 18F-PC-10 accumulated specifically in the inflamed paw 4- to 5-fold more than in the
control paw. Compared with 18F-PC-10, 18F-FDG and 64Cu-PTSM displayed higher accumulation
in the inflamed paw but also had higher accumulation in the control paw, demonstrating a reduced
signal-to-background ratio. 18F-PC-10 also accumulated in PKR1-expressing organs, such as the
salivary gland and gastrointestinal tract.
Conclusion—18F-PC-10 can be used to image PKR1, a biomarker of the inflammation process.
However, the high uptake of 18F-PC-10 in the gastrointestinal tract, due to specific uptake and the
metabolic processing of this highly lipophilic molecule, would restrict its utility.
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Prokineticin receptor 1 (PKR1) and prokineticin receptor 2 (PKR2) are closely related G-
protein–coupled receptors (1–3). PKR1 is widely distributed in the peripheral tissues,
including the gastrointestinal system, lungs, blood leukocytes, spleen, pancreas, testes,
salivary gland, and endocrine glands (1,4). The messenger RNA of both PKR1 and PKR2 is
expressed in the gastrointestinal system. However, whereas PKR1 is abundantly expressed
in the stomach, small intestine, colon, rectum, and other gastrointestinal tissues, PKR2 is
expressed only in the ileocecum, suggesting that PKR1 has a major role in the mediation and
regulation of gastrointestinal motility (1). PKR2 is also highly expressed in discrete nuclei
of the central nervous system (1,5,6).
The prokineticin Bv8—one of the ligands of PKR1—is a small protein (8 kDa) rich in
cysteine residues, which was isolated from the skin secretion of the frog Bombina variegata
(5,7,8). Homologs of Bv8 were found in skin secretions of other amphibians, lizards, and
fish (5). Mamba intestinal toxin-1 (MIT-1), found in the venom of the black mamba, is
another Bv8 homolog (5). The mammalian homologous proteins of Bv8 are prokineticin 1
(or vascular endothelial growth factor) and prokineticin 2 (or mBV8) (5,8,9).
Prokineticin proteins have been shown to promote angiogenesis, mainly in several endocrine
organs (10–12). These proteins are also involved in other biologic processes such as
reproduction, neuronal survival, neurogenesis, control of circadian rhythms, and cancer
(5,8,10,13–15). Another reported function of prokineticin proteins is to stimulate the
contraction of the isolated guinea pig ileum and relaxation of the colon (7,9,16). Prokineticin
2, but not prokineticin 1, is highly expressed in the bone marrow, lymphoid organs, and
leukocytes, suggesting a role for prokineticin 2 in hematopoiesis and in inflammatory and
immunomodulatory processes (17,18). Prokineticin 2 also plays a role in the regulation of
tumor-supporting myeloid cells (19). Shojaei et al. showed that Bv8 plays a role in the
mobilization of tumor angiogenesis, promoting myeloid cells from the bone marrow during
tumor development (19).
The prokineticin 2–PKR1 axis plays a major role in pain perception (4). Furthermore,
reduction in the pain threshold produced by prokineticin 2 acting on prokineticin receptors
in sensory neurons indicates that Bv8 and prokineticin and their receptors may act as
mediators of inflammatory and neuropathic pain (20–22). Giannini et al. showed that the
prokineticin 2–PKR1 axis plays a role in inflammation-related pain, demonstrating that
prokineticin 2 released by inflammatory cells can bind to activated PKR1 on primary
sensitive neurons and contribute to inflammatory pain (23). Blocking the prokineticin 2–
PKR1 axis might prove useful for reducing pain and for cancer therapy.
To this end, several nonpeptidic prokineticin antagonists have been developed (24–28).
However, there is no method to quantify the levels of PKR1 in vivo, to guide appropriate
treatment of candidates. In this study, we developed a biomarker based on the nonpeptidic
PKR1 antagonist N-{2-[5-(4-fluoro-benzyl)-1-(4-methoxy-benzyl)-4,6-dioxo-1,4,5,6-
tetrahydro-[1,3,5]triazin-2-ylamino]-ethyl}-guanidine (PC-7) (Fig. 1) for the noninvasive
quantification of PKR1 in an inflammatory pain model using PET. PC-7 contains a free
guanidine group and was labeled with the PET isotope 18F by coupling the guanidine
function to N-succinimidyl fluorobenzoate (18F-SFB), to give N-(4-18F-fluoro-benzoyl)-N′-
{2-[5-(4-fluoro-benzyl)-1-(4-methoxy-benzyl)-4,6-dioxo-1,4,5,6-tetrahydro-[1,3,5]triazin-2-
ylamino]-ethyl}-guanidine (18F-PC-10) (Fig. 1). 18F-PC-10 was further evaluated as a
biomarker in mice injected with complete Freund adjuvant (CFA), which was shown to
induce inflammatory pain by upregulation of prokineticin 2 and PKR1 (23).
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General Methods—Compounds were purified by preparative reversed-phase high-
performance liquid chromatography (HPLC) (δ-Prep 4000 system with a Prep LC 40-mm
assembly column C18; 30 × 4 cm, 15-μm particles; Waters) and eluted at a flow rate of 20
mL/min with mobile phase solvent A (10% acetonitrile + 0.1% trifluoroacetic acid [TFA] in
H2O, v/v) and a linear gradient from 10% to 60% B (60%, acetonitrile + 0.1% TFA in H2O,
v/v) for 25 min. Analytic HPLC analyses were performed with a System Gold device
(Ultrasphere ODS Column, 250 × 4.6 mm, 5-μm particles; Beckman). Analytic
determinations and the capacity factor (K′) of the products used for HPLC in solvents A and
B were programmed at flow rate of 1 mL/min with linear gradients from 0% to 100% B for
25 min. The analogs had less than 5% impurities at 220 and 254 nm.
The molecular weights of the compounds were determined by a matrix-assisted laser
desorption ionization time of flight analysis (G2025A LD-TOF system mass spectrometer;
Hewlett Packard) and α-cyano-4-hydroxycinnamic acid as a matrix. 1H-NMR (δ) spectra
were measured, when not specified, in dimethylsulfoxide-d6 solution using a spectrometer
(AC-200; Bruker), and peak positions are given in parts per million downfield from
tetramethylsilane as an internal standard. PC-7 was synthesized according to a published
procedure (29).
Synthesis of PC-10—PC-7 (1 equivalent) and LiOH•H2O (3 equivalents) were dissolved
in dimethylformamide. The solution was stirred in an oil bath at 100°C; 4-fluorobenzoic
acid (1 equivalent), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (1.1
equivalent), and 1-hydroxybenzotriazole (1.1 equivalent) were added in 1 pot as solids.
After 1 h at 100°C, the solvent was evaporated and the residue purified by preparative
HPLC: yield 40%; HPLC K′ 5.88; m/z 564.6 (M+H)+; 1H-NMR (dimethylsulfoxide-d6) δ
2.50–2.57 (m, 4H), 3.72 (s, 3H), 4.86 (s, 2H), 5.06 (s, 2H), 6.65–7.93 (m, 12H).
Radiochemistry
General Methods—Kryptofix 2.2.2 was purchased from EMD Chemicals. All other
solvents and chemicals were purchased from Sigma-Aldrich Co. Pyruvaldehyde bis(4-
methyl-3-thiosemicarbazone) (PTSM) was purchased from ABX GmbH. 18F-fluoride was
obtained from the National Institutes of Health Clinical Center cyclotron facility from the
irradiation of an 18O-water target by the 18O(p,n)18F nuclear reaction. C18 cartridges
(Waters Corp.) were each activated with 5 mL of ethanol and 10 mL of water. 18F-FDG was
purchased from Cardinal Health. 64Cu-PTSM was synthesized according to a published
procedure (30).
Radiosynthesis of 18F-PC-10—18F-PC-10 was synthesized in 2 radiochemical steps:
radiosynthesis of 18F-SFB and coupling of 18F-SFB with PC-7 to give the desired
product 18F-PC-10. 18F-SFB was radiosynthesized on a modular system (Eckert & Ziegler
Eurotope GmbH) according to a published procedure (31). 18F-SFB was redissolved in 150
μL of dimethylformamide. PC-7 (200 μg in 50 μL of dimethylformamide) was added,
followed by 20 μL of diisopropylethyl amine, and incubated at 60°C for 10 min.
18F-PC-10 was purified on a reversed-phase HPLC system using a Vydac C4 (214TP510, 5
μm, 10 × 250 mm; Grace) column. The flow was set at 4 mL/min using a gradient system
starting from 70% solvent A and 30% solvent B and increasing to 35% solvent A and 65%
solvent B at 30 min. The retention time (Rt) of 18F-PC-10 on this system was 15.1 min. The
HPLC solution of 18F-PC-10 was diluted with 10 mL of water and loaded on an activated
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C-18 cartridge. The cartridge was washed with 10 mL of water, and 18F-PC-10 was eluted
with 80% ethanol. The ethanol was completely evaporated under a stream of argon, and 18F-
PC-10 was formulated in saline with the addition of 50 μL of dimethyl-sulfoxide, to prevent
tackiness to the glass tube.
18F-PC-10 quality control was monitored using analytic reversed-phase HPLC on a Vydac
C4 (214TP5415, 5 μm, 4.6 × 150 mm) column with a gradient system starting from 100%
solvent A (0.1% TFA in water) and 0% solvent B (0.1% TFA in acetonitrile) for 5 min and
increasing to 50% solvent A and 50% solvent B at 30 min (flow, 1 mL/min; Rt, 25.81 min).
The ultraviolet absorbance was monitored at 254 nm, and the identification of 18F-PC-10
was confirmed by a coinjection with unlabeled PC-10. The Rt of unlabeled PC-10 was 25.65
min.
Biology
Chinese Hamster Ovarian (CHO)-PKR1 and CHO-PKR2 Cell Culture—CHO-
PKR1 and CHO-PKR2 cell lines were kindly provided by Dr. Qun-Yong Zhou from the
University of California–Irvine. The cells were grown in Dulbecco’s modified Eagle’s
medium (Gibco) supplemented with 10% (v/v) fetal bovine serum under 5% CO2 at 37°C.
Competition Cell-Binding Assay—PKR1 and PKR2 binding was assayed to determine
binding affinities of PC-10. Briefly, CHO-PKR1 and CHO-PKR2 cells were cultured in
Dulbecco’s modified Eagle’s medium with fetal bovine serum. When cells reached 80%
confluence, they were scraped off and suspended with binding buffer (20 mM Tris-HCl, pH
7.4, 150 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, and 1 mM MnCl2, 0.1% bovine serum
albumin) for a final concentration of 2 × 106 cells/mL. In a 96-well plate, 1 × 105 of either
CHO-PKR1 or CHO-PKR2 cells per well were incubated with 1.11 kBq/well (0.03 μCi/
well) of 125I-MIT-1 (Perkin-Elmer) in binding buffer in the presence of different
concentrations of PC-10 at room temperature for 2 h. After incubation, the plate was washed
3 times with phosphate-buffered saline (PBS), and the radioactivity was measured by γ-
counting. The inhibitory concentration of 50% (IC50) was calculated by nonlinear regression
analysis using the GraphPad Prism computer-fitting program (GraphPad Software, Inc.).
Each data point is a result of the average of duplicate wells.
Cell Uptake, Internalization, and Efflux Studies—For cell uptake studies, CHO-
PKR1 cells were seeded into a 24-well plate at a density of 1 × 105 cells per well and
incubated with 444 kBq/well (12 μCi/well) of 18F-PC-10 at 37°C for 15, 30, 60, and 120
min. Tumor cells were then washed twice with cold PBS and harvested by addition of 250
μL of 0.1 M NaOH. Internalization studies were performed similarly to the procedure
described for the cell uptake studies. After 15, 30, 60, and 120 min of incubation of CHO-
PKR1 cells with 18F-PC-10 at 37°C, the cells were washed twice with cold PBS and then
incubated for 1 min with acid-washing buffer (50 mmol/L glycine, 0.1 M NaCl, pH 2.8) to
remove surface-bound radioactive ligand. Thereafter, the cells were washed twice with cold
PBS and harvested by addition of 250 μL of 0.1 M NaOH. For efflux studies, 444 kBq/well
(12 μCi/well) of 18F-PC-10 were added to CHO-PKR1 cells in a 24-well plate and
incubated for 2 h at 37°C. Then cells were washed twice with cold PBS and incubated with
Dulbecco’s modified Eagle’s medium for 15, 30, 60, and 120 min. After being washed twice
with PBS, cells were harvested by addition of 250 μL of 0.1 M NaOH. The cell suspensions
were collected and measured in a γ-counter (1480 Wizard 3; Perkin-Elmer). Each data point
is an average of triplicate wells.
CFA Inflammation Model—CFA (Sigma-Aldrich) was emulsified with PBS in a 1:1 ratio
and injected subcutaneously into the paw in a volume of 20 μL. Inflammation-induced pain
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was shown to peak at 24 h after CFA injection; hence, 18F-PC-10, 18F-FDG, or 64Cu-PTSM
was administered at that time point. Inflammation was verified visually by inspection of the
draining lymph node.
PET Studies—CFA-injected mice were anesthetized using isoflurane/O2 (1.5%–2% v/v)
and injected with 1.85–3.7 MBq (50–100 μCi) of 18F-PC-10, 18F-FDG, or 64Cu-PTSM in a
volume of 100 μL of PBS. For blocking experiments, 1.85–3.7 MBq (50–100 μCi) of 18F-
PC-10 were coinjected with 350 μg of unlabeled PC-7. PET scans were obtained using an
Inveon DPET scanner (Siemens Medical Solutions) at 0.5, 1, and 2 h after injection. Each
group contained 3–5 mice. The images were reconstructed by a 3-dimensional ordered-
subsets expectation maximum algorithm, and no correction was applied for attenuation or
scatter. Images were analyzed using ASI Pro VM software. The percentage injected dose per
gram (%ID/g) for the various tissues was determined by drawing regions of interest
surrounding the paws on the coronal images. The radioactivity contained in the region of
interest divided by the dose administered to the animal gave the %ID, and the volume of the
region of interest was converted to mass assuming a density of 1 for the tissue.
Biodistribution—At 2 h after injection of 18F-PC-10, mice were anesthetized and their
blood was drawn from the heart. The liver, muscle, kidneys, gastrointestinal tract, bone,
salivary gland, and control and inflamed paws were removed. The organs were weighed and
assayed for radioactivity using a γ-counter (1480 Wizard 3; Perkin-Elmer). Each group
contained 4–5 mice.
Statistical Analysis
Results were expressed as mean ± SD. Two-tailed paired and unpaired Student t tests were
used to determine differences within groups and between groups, respectively. P values of
less than 0.05 were considered statistically significant.
RESULTS
Synthesis of PC-10
The nonpeptidic PKR1 antagonist PC-7 was synthesized according to a published procedure
(29). PC-7 was coupled with 4-fluorobenzoic acid for 1 h at 100°C using the coupling
reagents N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride and 1-
hydroxybenzotriazole to give PC-10 as a white powder in a 40% yield (Fig. 1A).
Radiosynthesis of 18F-PC-10
18F-SFB conjugation to PC-7 occurred on a free guanidine group in the presence of a base
(Fig. 1B). The conjugation was done with moderate heating for 10 min. Analytic HPLC was
performed to follow the conversion to the desired 18F-PC-10 and the consumption of 18F-
SFB.
When only 100 μg of PC-7 were used, there was still unreacted 18F-SFB (Rt, 10.91 min)
remaining, as detected by analytic HPLC (Fig. 2). There is also a formation of 4-18F-
fluorobenzoic acid (Rt, 4.09 min) due to the basic conditions of the coupling reaction. The
formation of 18F-PC-10 can be clearly seen by elution of the radioactive peak at a Rt of
25.81 min (Fig. 2). There are several other unidentifiable radioactive peaks formed during
the coupling reaction.
18F-PC-10 was purified on a reversed-phase HPLC system and was achieved with
radiochemical and chemical purities both greater than 99% and a specific activity of 70.3 ±
7.4 TBq/mmol (1,900 ± 200 Ci/mmol) at the end of synthesis. The overall decay-corrected
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yield of 18F-PC-10 was 16% ± 3% (n = 4), based on 18F-fluoride radioactivity at the start of
synthesis. The average total synthesis time, including HPLC purification and formulation,
was about 160 min.
Competitive Binding Assay with 125I-MIT-1
The affinity of PC-10 to CHO cells transfected with either human PKR1 or human PKR2
was evaluated in a competitive binding assay with the commercially available Bv8 homolog
MIT-1, labeled with 125I (125I-MIT-1). The IC50 of PC-10 binding to CHO-PKR1 cells was
much lower than that achieved for PC-10 binding to CHO-PKR2 cells (109.7 ± 4.91 vs.
1,200 ± 69.47 nM, respectively). The binding affinity of PC-10 to PKR1 is 3-fold lower than
the functional IC50 of PC-7 (33 nM) required to induce calcium mobilization in human
PKR1–expressing cells, as previously reported in the literature (29).
Uptake, Internalization, and Efflux Studies
The cell uptake, internalization, and efflux of 18F-PC-10 were evaluated in CHO-PKR1
cells. 18F-PC-10 uptake increased between 15 min and 0.5 h (Fig. 3A), reached a plateau at
0.5 h, and remained at a similar level for up to 1 h. There was a slight decrease in the uptake
between 1 and 2 h (Fig. 3A). To evaluate the internalization of the tracer, cells were treated
with acid buffer (pH 2.8) before the final wash. Approximately half of the observed uptake
was due to internalization of 18F-PC-10 into the cells. The internalization also reached a
plateau at 0.5 h, remaining stable up to 2 h after incubation. Retention studies showed a
rapid release of 18F-PC-10 by CHO-PKR1, and within 15 min after the replacement of the
medium, half of the activity was unbound and reached a plateau after 1 h.
PET and Biodistribution
The targeting efficiency of 18F-PC-10 in a CFA-induced inflammatory pain model in mice
was evaluated by static small-animal PET scans. 18F-PC-10 had clearly higher accumulation
in the inflamed paw than in the control paw (Fig. 3B). 18F-PC-10 had an uptake of 0.95 ±
0.20 %ID/g in the inflamed paw at 0.5 h after injection. This uptake was slightly increased at
1 h (1.21 ± 0.32 %ID/g, Fig. 4A). At 2 h after injection, the uptake decreased to 0.78 ± 0.04
%ID/g in the inflamed paw and from 0.25 ± 0.06 %ID/g to 0.13 ± 0.01 %ID/g in the control
paw (Fig. 4A). At all time points, 18F-PC-10 uptake in the inflamed paw was significantly
higher than in the control paw (P < 0.01, Fig. 4A).
To determine the PKR1 specificity of 18F-PC-10 in vivo, CFA-treated mice were coinjected
with 18F-PC-10 and an excess amount of the potent PKR1 antagonist PC-7. The uptake in
the inflamed paw decreased significantly by approximately 70% at 1 h after injection (0.35 ±
0.01 %ID/g), confirming specific binding of 18F-PC-10 to PKR1 (Fig. 4A).
18F-PC-10 also accumulated in PKR1-expressing organs (Figs. 3B and 4B), such as the
salivary gland (3.05 ± 1.10 %ID/g at 2 h after injection) and gastrointestinal tract (54.3 ± 2.5
%ID/g at 2 h after injection). 18F-PC-10 had fast clearance from the blood (0.22 ± 0.05
%ID/g at 2 h after injection) and moderate uptake in the liver and kidneys (3.80 ± 1.14 and
5.26 ± 1.06 %ID/g, respectively, at 2 h after injection, Fig. 4B). 18F-PC-10 uptake in the
bone was low (0.69 ± 0.12 %ID/g at 2 h after injection, Fig. 4B), suggesting that there is no
significant defluorination in vivo.
To compare the efficiency of 18F-PC-10 as a biomarker for inflammation, CFA-treated mice
were injected with 18F-FDG—which measures glucose metabolism rate and is known to
accumulate in inflammatory foci (32,33)—and scanned at 0.5, 1, and 2 h after injection (Fig.
5A). At all time points, 18F-FDG uptake was higher than 18F-PC-10 uptake in the inflamed
paw. For example, at 1 h, 18F-FDG uptake in the inflamed paw was 4.98 ± 0.28 %ID/g (Fig.
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5A), which is almost 5 times higher than the uptake achieved with 18F-PC-10. This
difference was further increased at 2 h after injection, because 18F-PC-10 started to undergo
clearance. 18F-FDG uptake in the inflamed paw, however, remained stable and high,
because of its retention mechanism within the cell (5.21 ± 0.29 %ID/g, Figs. 4A and 5A).
In addition, 18F-PC-10 uptake in the inflamed paw was compared with CFA-treated mice
injected with the perfusion imaging agent 64Cu-PTSM. 64Cu-PTSM also had higher uptake
in the inflamed paw than did 18F-PC-10 at all time points (Fig. 5B). 64Cu-PTSM uptake in
the inflamed and control paws was stable at all time points (~3.50 %ID/g in the inflamed
paw and 1.60 %ID/g in the control paw, Fig. 5B).
Uptake in the control paw was much higher for both 18F-FDG and 64Cu-PTSM than for 18F-
PC-10. 18F-FDG and 64Cu-PTSM uptake in the inflamed paw was only 2-fold higher than in
the control paw (Fig. 5). In contrast, 18F-PC-10 uptake was 4–5 times higher in the inflamed
paw than in the control paw (Fig. 4). The ratios between the inflamed and control paws at all
time points show that the inflamed paw–to–control paw ratio is higher for 18F-PC-10 than
for either 18F-FDG or 64Cu-PTSM (Fig. 6).
DISCUSSION
Prokineticin receptors are G-protein–coupled receptors belonging to the neuropeptide Y
receptor class, and their importance is emphasized by the fact that one of their ligands, MIT,
is present in snake venom (5). The prokineticin 2–PKR1 axis was shown to be expressed in
inflamed tissue and was suggested as a link between cells infiltrating the inflamed tissue and
the development of inflammatory pain (23). Giannini et al. have demonstrated that the
development and duration of CFA-induced hyperalgesia correlates with the messenger RNA
expression level of prokineticin 2 in the inflamed paw, and they have shown that 24 h after
CFA induction, there is elevation in messenger RNA expression of PKR1 (23). One possible
explanation for higher PKR1 expression in the inflamed tissue is that prokineticin 2, which
was also shown to have chemotactic capability, induces accumulation of cells that express
its receptor.
To quantify PKR1 levels in inflammation induced by CFA injection, we modified the
known nonpeptidic PKR1 antagonist PC-7 (29). PC-7 contains a free guanidine group and
was conjugated with p-fluorobenzoic acid to give PC-10 (Fig. 1A). The affinity of PC-10 to
PKR1 and PKR2 was tested and demonstrates that PC-10 is more selective and potent to
PKR1 than to PKR2.
PC-7 was also used as a precursor for the labeling with 18F (Fig. 1B). PC-10 was labeled
with 18F via conjugation of PC-7 with 18F-SFB. 18F-SFB is a prosthetic group, which is
usually used in peptide labeling for coupling to ε- or α-amino groups (31,34,35). PC-7 was
conjugated with 18F-SFB in dimethylformamide in the presence of a base and for a short
reaction time. One of the byproducts of the coupling reaction was 18F-fluorobenzoic acid
(Fig. 2). Because the reaction was conducted in dimethylformamide and base
(diisopropylethyl amine), the formation of both 18F-PC-10 and 18F-fluorobenzoic acid was
rapid. Increasing the amount of PC-7 used for the radiosynthesis (from 100 to 200 μg)
resulted in a higher radiochemical yield of 18F-PC-10 and complete elimination of 18F-SFB.
Increasing the amount of PC-7 even more did not change significantly the reaction kinetic
and yield. Unreactive PC-7 was detected by ultraviolet absorbance (data not shown).
Attempts to use only 100 μg of PC-7 resulted in unreactive 18F-SFB (Fig. 2). When
additional base was added to improve the conversion to 18F-PC-10, decomposition of 18F-
SFB to 18F-fluorobenzoic acid was detected, along with an overall decrease in the
radiochemical yield of desired product.
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Inflammation-related pain was induced in C57BL/6 mice by subcutaneous injection of CFA
into the right paw, and 24 h later, the mice were injected intravenously with 18F-PC-10. 18F-
PC-10 was clearly visualized in the inflamed paw (Figs. 3B), and the uptake in the inflamed
paw was 4- to 5-fold higher at all time points (0.5, 1, and 2 h) than the uptake in the control
paw (Fig. 4A). 18F-PC-10 uptake in the inflamed paw was decreased at 2 h after injection,
suggesting that the optimal imaging time with 18F-PC-10 should not exceed 2 h after
injection. This result is in accordance with the cell studies, with optimal uptake of 18F-
PC-10 at 1 h after incubation and some reduction in the activity on the cells at 2 h. Blocking
studies by coinjection of 18F-PC-10 and the more potent PKR1 antagonist PC-7 (which has a
chemical structure similar to that of PC-10) showed a significant decrease in the inflamed
paw uptake, suggesting a specific binding to PKR1 (Fig. 4A).
18F-PC-10 also displayed uptake in PKR1-expressing organs, such as the salivary gland and
gastrointestinal tract. Low uptake in the kidneys and liver (Fig. 4B) and increased uptake in
the gastrointestinal tract suggest that the main clearance route of 18F-PC-10 is via the small
intestine and colon, which means that the radioactivity in the gastrointestinal tract is not
solely due to specific binding to PKR1. Clearance via the gastrointestinal tract could
possibly be because of the lipophilicity of 18F-PC-10, and modification of the small
molecule to be more hydrophilic might change the pharmacokinetics and enable the
visualization of specific binding of 18F-PC-10 to PKR1 in the lower abdomen, including the
intestine. The high uptake in the intestine is most unfortunate, because several conditions
could induce inflammatory pain in this organ (36).
Another issue that we addressed here was the possibility that the higher accumulation in the
inflamed paw was due to the inflammatory process, which may cause regional increases in
blood flow, vascular permeability, and extracellular volume that result in nonspecific uptake
of biomarkers. For these reasons, we compared 18F-PC-10 uptake with 18F-FDG and 64Cu-
PTSM uptake in the inflamed paw. 18F-FDG measures the glucose metabolic rate and is
mainly used as a cancer imaging agent but also accumulates in inflammatory lesions
(32,33). 64Cu-PTSM is known as a perfusion imaging biomarker and should be able to
determine blood flow to the region (37,38).
18F-FDG and 64Cu-PTSM had 2-fold higher uptake in the inflamed paw than in the control
paw at all time points, implying that there is high blood flow in the CFA-treated animal
model that we used. Neither of these tracers is specific. They can give information regarding
perfusion and metabolism but cannot give any biochemical information regarding the
inflammation. Although 18F-FDG and 64Cu-PTSM had significantly higher uptake than 18F-
PC-10 in the inflamed paw (Figs. 4A and 5), they also had significantly higher uptake
than 18F-PC-10 in the control paw (10-fold higher).
Therefore, a comparison of the ratio of inflamed paw to control paw (Fig. 6) shows that 18F-
PC-10 has an advantage over 18F-FDG and 64Cu-PTSM in term of less background (less
accumulation in the control paw), leading to higher PET image contrast between the
inflamed and control paws. In addition, 18F-PC-10 binds specifically to PKR1 in vivo and
gives information that might be helpful for therapeutic intervention for inflammation-related
pain.
CONCLUSION
Overall, we successfully labeled the selective nonpeptidic PKR1 ligand 18F-PC-10. A CFA
injection induced 18F-PC-10 specific uptake in the inflamed paw that expressed PKR1. 18F-
PC-10 showed a higher inflamed paw–to–control paw ratio than 18F-FDG and 64Cu-PTSM,
resulting in better PET contrast. PKR1 and PKR2 should be further investigated as potential
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targets for the imaging of pain. More hydrophilic imaging agents can be developed and may
improve the image quality.
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(A) Nonradioactive synthesis of PC-10. (B) Radioactive synthesis of 18F-PC-10. DIPEA =
diisopropylethyl amine; DMF = dimethylformamide; HOBt = 1-hydroxybenzotriazole; WSC
= N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride.
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Radioactive analytic HPLC of crude sample of conjugation reaction of PC-7 (100 μg)
with 18F-SFB to give 18F-PC-10. mAU = milliabsorbance unit.
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(A) Cell uptake, internalization, and efflux assays of 18F-PC-10 in CHO-PKR1 cells. (B)
Representative coronal (right) and axial (left) PET images of a C57BL/6 mouse injected
with CFA into right paw at 1 h after injection with 3.7 MBq (100 μCi) of 18F-PC-10.
Arrows indicate inflamed paw. CPM = counts per min.
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(A) Uptake of 18F-PC-10 in inflamed, control, and inflamed-block paws of C57BL/6 mice,
treated with CFA at 24 h before imaging and at 0.5, 1, and 2 h after injection. Results are
calculated from PET scans and are shown as averages of 4–5 mice ± SD. (B) Biodistribution
of C57BL/6 CFA–treated mice injected with 18F-PC-10 at 2 h after injection. Results shown
are averages of 4–5 mice ± SD. CTRL = control. *P < 0.01 vs. control paw. #P < 0.05 vs.
inflamed-block paw.
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(A; left) Representative coronal PET image of C57BL/6 mouse injected with CFA into right
paw at 1 h after injection with 3.7 MBq (100 μCi) of 18F-FDG. (Right) Uptake of 18F-FDG
in inflamed and control paws of C57BL/6 mice, treated with CFA at 24 h before imaging
and at 0.5, 1, and 2 h after injection. Results are calculated from PET scans and are shown as
averages of 3–4 mice ± SD. (B; left) Representative coronal PET image of C57BL/6 mouse
injected with CFA into right paw at 1 h after injection with 3.7 MBq (100 μCi) of 64Cu-
PTSM. (Right) Uptake of 64Cu-PTSM in inflamed and control paws of C57BL/6 mice,
treated with CFA at 24 h before imaging and at 0.5, 1, and 2 h after injection. Results are
calculated from PET scans and are shown as averages of 3–4 mice ± SD. CTRL = control.
*P < 0.01 vs. control paw.
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Inflamed paw–to–control paw ratios of either 64Cu-PTSM (white bars), 18F-FDG (hatched
bars), or 18F-PC-10 (black bars) at 0.5, 1, and 2 h after injection. Results shown are averages
of 3–5 mice ± SD. CTRL = control.
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